February 22, 2022

Press Stunting Figures, Phapros Develops Curlysine

JAKARTA, 22 Februari 2022

Phapros, Tbk, which is one of the national pharmaceutical companies, continues to innovate to expand its business. One of the products resulting from Phapros' innovation is Curlysine, a supplement that increases children's appetite.

Phapros CEO, Hadi Kardoko, said that one of the considerations for developing the product is the high number of cases of stunting due to malnutrition in Indonesia.

"Based on the results of the Indonesia Nutritional Status Study (SSGI) conducted by the Ministry of Health in collaboration with BPS and the Acceleration Team for the Prevention of Dwarf Children under the Vice President's Secretariat in 2021, the national stunting rate has decreased by 1.6 percent per year from 27.7 percent in 2019 to 24.4 percent in 2021. Almost all of the 34 provinces show a decline compared to 2019, and only 5 provinces show an increase. However, the prevalence of stunting cases in Indonesia is still higher than in Vietnam (23 percent), Malaysia (17 percent), Thailand (16 percent), and Singapore (4 percent). Therefore, various family-based interventions are needed to reduce the risk of stunting, including the provision of food supplements for children if necessary," said Hadi.

Curlysine is a food supplement for children that contains a combination of curcuma extract, lysine, and taurine. Scientifically, curcuma extract can be used for digestive disorders and to improve appetite, including as an immunomodulator. Lysine is an essential amino acid that is necessary for nerve development in children and to prevent stunting. Taurine plays an important role in maintaining cell integrity in several organs of the body. Thus, children's overall health can be maintained.

"We target to sell 40,350 units of this product in the next year," said Hadi. Previously, this stock-coded issuer (PEHA) was optimistic about double-digit growth in 2022, mainly driven by the development and innovation of new products.